BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study [0.03%]
BMS-986012：一种抗岩藻糖基GM1单克隆抗体，作为单药或与纳武利尤单抗联合治疗复发/难治性小细胞肺癌：一项I/II期首次人体研究结果
Quincy Chu,Natasha B Leighl,Veerle Surmont et al.
Quincy Chu et al.
Introduction: Fucosyl-GM1 is a monosialoganglioside with limited expression in healthy tissues and high expression on SCLC cells. BMS-986012 is a nonfucosylated, first-in-class, fully human immunoglobulin G1 monoclonal an...
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data [0.03%]
基于日本帕博利珠单抗上市后再审查数据库的晚期非小细胞肺癌患者单药治疗的现实世界数据分析
Hideki Terai,Kenzo Soejima,Asanao Shimokawa et al.
Hideki Terai et al.
Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on...
Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastases-a Single-Center Study in 190 Patients [0.03%]
肺癌及其脑转移癌中程序性死亡配体-1的表达——一项单中心190例患者的分析研究
Alexandra Kündig,Philipp Zens,Christian Fung et al.
Alexandra Kündig et al.
Introduction: Expression of programmed death-ligand 1 (PD-L1) is the only routinely used tissue biomarker for predicting response to programmed cell death protein 1/PD-L1 inhibitors. It is to date unclear whether PD-L1 ex...
Acquired Hemophilia A Secondary to an Immune Checkpoint Inhibitor: A Case Report [0.03%]
免疫检查点抑制剂引起的获得性血友病A的病例报告
James Fletcher,Robert Bird,Andrew J W McLean et al.
James Fletcher et al.
We report a case of a patient with extensive-stage SCLC who developed acquired hemophilia A during maintenance atezolizumab therapy. The patient initially presented with asymptomatic anemia, a prolonged acquired prothrombin time, and factor...
Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature [0.03%]
低剂量达卢派宗治疗奥希替尼引起的皮肤血管炎：1例报告及文献回顾
Christopher Iriarte,Jonathan H Young,Michael S Rabin et al.
Christopher Iriarte et al.
A 45-year-old woman with a history of lung adenocarcinoma treated with osimertinib developed purpuric plaques and vesicles on the lower extremities after 5 months of therapy. Skin biopsy revealed leukocytoclastic vasculitis (LCV). A workup ...
A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC [0.03%]
L-DOS47联合培美曲塞和卡铂治疗IV期复发或转移性非鳞状非小细胞肺癌患者的I期开放标签剂量递增研究
Sarina Piha-Paul,George Simon,Chandra P Belani et al.
Sarina Piha-Paul et al.
Introduction: L-DOS47, a targeted urease-anti-CEACAM6 immunoconjugate, alters the acidity of the tumor microenvironment by increasing local ammonia production. In vitro, the cytotoxic effects of L-DOS47 were additive when...
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC [0.03%]
克唑替尼治疗ROS1阳性晚期非小细胞肺癌的东部亚裔患者最终总生存率、安全性和生活质量的Ⅱ期临床研究结果
Yi-Long Wu,Shun Lu,James Chih-Hsin Yang et al.
Yi-Long Wu et al.
Introduction: Crizotinib provided meaningful clinical benefit in the initial analysis of a phase 2 study in East Asian patients with advanced ROS1-positive NSCLC (NCT01945021). Nevertheless, overall survival (OS) data wer...
Successful Management of Generalized Myasthenia Gravis Induced by Atezolizumab in a Patient With Extensive-Stage SCLC: A Case Report [0.03%]
阿特珠单抗诱导的广泛期小细胞肺癌患者的全身性肌无力症的管理：病例报告
Shuang Wu,Jiayu Shi,Yuzhou Guan et al.
Shuang Wu et al.
Immune checkpoint inhibitors including atezolizumab and durvalumab have been approved as the first-line treatment in extensive-stage SCLC. However, immune checkpoint inhibitors can cause immune-related adverse events, which will lead to the...
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations [0.03%]
卡马替尼治疗中国MET外显子14跳变NSCLC患者的真实世界疗效和安全性分析及亚组研究
Shun Lu,Jian Fang,Xingya Li et al.
Shun Lu et al.
Introduction: Savolitinib has been found to have encouraging antitumor activity and a favorable safety profile in Chinese patients with pulmonary sarcomatoid carcinoma and other NSCLCs with MET exon 14 skipping alteration...
Assessing Oncologists' Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil [0.03%]
巴西针对IV期肺腺癌的全面基因组谱分析肿瘤学家的态度评估
Aline F Fares,Pedro H Martinez,Pedro H Farina et al.
Aline F Fares et al.
Introduction: Advances in comprehensive genomic profiling (CGP) of lung adenocarcinomas (LUADs) led to personalized treatment for patients. This study evaluated medical oncologists' attitudes toward CGP in a scenario wher...